Loading…
Pasithea Therapeutics Corp.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.1% over 5Y.
today you would have $8.21▼ -99.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.29 | $3.15 | $7.40 | $12.84 | $35.40 | |
| P/S | — | — | — | — | 34.5x | 2686.2x |
| P/B | 0.6x | 0.6x | 0.6x | 0.3x | 0.4x | 0.8x |
| EPS | -$2.91 | -$12.69 | -$0.42 | -$1.76 | -$4.20 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PTNPalatin Technologies Inc | $10.48 | 95.3x | 1.8x | — | -297.24% | $18.65M |
| NCELNewcelX Ltd. | $3.19 | — | 2.1x | — | — | $18.43M |
| BIVIBiovie Inc | $2.16 | — | 1.6x | — | -150.76% | $18.25M |
| PMIPicard Medical, Inc. | $8.80 |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Company description provided by Yahoo Finance.
| Profit margin | — | — | — | — | -2864.29% | -14430.49% |
| ROE | -36.99% | -36.99% | -94.06% | -68.22% | -32.79% | -4.23% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 10.5x |
| — |
| — |
| $18.07M |
| LPCNLipocine Inc. | $2.17 | — | 0.8x | — | -60.94% | $17.89M |
| QNTMQuantum Biopharma Ltd. | $3.08 | — | 2.9x | — | -621.46% | $19.77M |